查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1978935

植物生物技术设备市场：按设备类型、技术、工作流程阶段、应用和最终用户划分－2026年至2032年全球市场预测

Plant Biotechnology Equipment Market by Instrument Type, Technology, Workflow Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，植物生物技术设备市场价值将达到 159 亿美元，到 2026 年将成长至 179.1 亿美元，到 2032 年将达到 370.5 亿美元，复合年增长率为 12.84%。

主要市场统计数据
基准年 2025 159亿美元
预计年份：2026年 179.1亿美元
预测年份 2032 370.5亿美元
复合年增长率 (%) 12.84%

简要概述了技术、营运和商业性因素在重组植物生物技术设备采购和实验室工作流程中的整合。

随着创新者、服务供应商和研究机构追求更高的通量、更强的可重复性和更整合的工作流程，植物生物技术设备市场正在快速发展。本文总结了推动基因工程、定序和表型分析等实验室和生产设备投资和应用成长的因素，并概述了重塑整个领域采购、营运和协作的因素。

模组化平台、循环消耗品、数据驱动型服务以及对永续性的重视，正在从根本上重塑设备策略和供应商差异化。

植物生物技术仪器市场正经历一系列相互关联的变革，这些变革涵盖了从实验室到现场应用、从仪器设计到商业服务模式的各个方面。首先，模组化和工作流程整合正在重新定义产品蓝图。在实验室中，能够实现样品製备、定序或合成以及下游分析之间快速转换的平台正日益受到青睐。这种对资料和材料无缝流动的重视促使供应商提供捆绑式解决方案、更强大的软体整合以及预检验通讯协定，从而缩短结果获取时间并简化监管验证流程。

我们将评估美国最近的关税措施对整个价值链的筹资策略、製造地、消耗品供应的连续性以及采购风险管理的影响。

近期美国关税及相关贸易措施的累积影响，为植物生物技术设备的采购计画、供应链建构和定价策略带来了新的变数。在交易层面，零件和成品设备进口关税的提高可能会压缩利润空间或推高终端用户的标价，迫使企业重新评估筹资策略并探索替代供应管道。因此，采购团队正在重新评估其供应商组合和规格，并寻求从国内或免税地区采购零件和子系统。

针对每个工作流程阶段，透过细分市场来主导设备子类别、应用需求、技术选项、最终使用者采购行为和优先级，从而指导目标策略。

精确的细分观点揭示了不同仪器类型、应用、技术、终端使用者和工作流程阶段所面临的独特机会和挑战。仪器包括生物反应器、DNA定序仪、微阵列系统和PCR系统，每个类别都呈现各自的子类别发展趋势。生物反应器正根据生产规模和检验要求的不同，分化为一次性使用型和不銹钢型。 DNA定序仪分为次世代定序（NGS）平台和传统的Sanger定序系统，其中NGS推动了对高通量检验的大部分需求。微阵列系统专注于基因表现分析和SNP分析，每个应用场景都决定了阵列密度和分析需求。 PCR系统已发展为数位PCR和qPCR模式，其中数位PCR因其灵敏度和绝对定量能力而备受青睐。

区域采购週期、监管预期和服务网路要求会影响美洲、欧洲、中东和非洲以及亚太地区的设备部署。

区域趋势对美洲、欧洲、中东和非洲（EMEA）以及亚太地区的采购週期、监管预期和伙伴关係模式产生显着影响。在美洲，由研究机构、生物技术Start-Ups和成熟製造商组成的强大生态系统塑造了以整合平台、完善的售后服务和本地试剂供应链为重点的需求格局。这种环境也推动了次世代定序和基因编辑工作流程的快速早期应用，而采购决策则受到机构津贴週期和私人投资模式的影响。

竞争格局分析，展示了成熟的平台公司、利基创新者、消费生态系统和服务整合商如何建立长期竞争优势。

植物生物技术仪器领域的竞争格局呈现出多元化的特点，既有成熟的平台公司，也有专注于创新的专业厂商和垂直整合的供应商，这模糊了仪器供应商和服务供应商之间的界线。成熟的仪器製造商在平台可靠性、处理能力和丰富的耗材生态系统方面展开竞争，而专注于特定领域的供应商则致力于提升灵敏度、小型化和自动化等性能差异化优势，以解决特定的工作流程瓶颈。这种竞争格局推动着持续的渐进式创新，供应商不断改进光学、流体控制、热控制和软体，以扩大其产品在目标应用领域的普及程度。

为製造商和服务供应商提供切实可行的策略步骤，以增强韧性、深化客户价值并抓住产品和服务差异化机会。

产业领导企业应采取果断且具有前瞻性的措施，透过对製造柔软性、产品架构和客户参与进行有针对性的投资，将颠覆性趋势转化为策略优势。首先，他们应加快模组化产品设计，以便在不重新设计整个平台的情况下更换受影响的子组件。这将降低关税造成的供应衝击风险，并缩短本地化生产所需的认证流程时间。透过模组化设计，企业可以提供可扩展的配置，既能满足研发实验室的需求，又能满足商业规模营运的需求，进而拓展目标应用场景。

我们采用混合研究途径，结合与关键相关人员的访谈、技术产品审查和政策研究，得出检验且可操作的见解。

本研究采用三角测量调查方法综合结果，该方法结合了质性访谈、二手文献整合以及针对特定产品和政策的研究。关键输入资料包括对学术界、工业界和服务供应商等各领域研究机构负责人、采购专家、设备工程师和商业部门领导者的结构化访谈。这些访谈重点在于采购驱动因素、检验流程、供应链脆弱性以及资料分析在设备部署中的作用。

总结了以下见解，阐述了工作流程整合、供应链弹性以及以数据为中心的服务为何能够推动整个产业的竞争成功。

总之，受技术成熟度、采购预期变化以及地缘政治和贸易因素的驱动，植物生物技术仪器市场正经历战略转型。仪器创新正与软体主导的分析和以耗材为中心的经营模式融合，竞争焦点也从独立仪器转向能够提供可重复结果的、检验的端到端工作流程。这种演变有利于那些不仅拥有技术能力，而且拥有强大的服务网络、检验的通讯协定和供应链韧性的供应商。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：植物生物技术设备市场：依设备类型划分

  • 生物反应器
    • 一次使用
    • 不銹钢
  • DNA定序仪
    • 次世代定序
    • 桑格定序
  • 微阵列系统
    • 基因表现
    • SNP分析
  • PCR系统

第九章：植物生物技术设备市场：依技术划分

  • CRISPR工具
    • 质体导入
    • 核糖核蛋白
  • 次世代定序
  • PCR技术

第十章：植物生物技术设备市场各阶段工作流程

  • 分析
    • 生物资讯学
    • 数据视觉化
  • 样品製备
    • DNA萃取
    • 样品製备
  • 合成
    • 基因合成
    • 寡核苷酸合成

第十一章：植物生物技术设备市场：依应用领域划分

  • 基因编辑
  • 基因分析
    • 表达分析
    • 基因型鉴定
  • 表型分析
    • 影像分析
    • 感测器基座
  • 组织培养
    • 癒伤组织培养
    • 原生质体培养

第十二章：植物生物技术设备市场：依最终用户划分

  • 学术机构
    • 研究中心
    • 大学
  • 生技公司
    • 农业生物技术
    • 製药和生物技术
  • 合约研究机构
  • 製药公司

第十三章：植物生物技术设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：植物生物技术设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：植物生物技术设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国植物生物技术设备市场

第十七章：中国植物生物技术设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • LabRepCo
  • LemnaTec GmbH
  • LGC Limited
  • Merck KGaA
  • Microsil India Pvt. Ltd.
  • Narang Scientific Works Pvt. Ltd.
  • Neu-tec Group Inc.
  • PerkinElmer, Inc.
  • Sartorius AG
  • Shimadzu Corporation
  • Tecan Group Ltd.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-521BAA36EA76

The Plant Biotechnology Equipment Market was valued at USD 15.90 billion in 2025 and is projected to grow to USD 17.91 billion in 2026, with a CAGR of 12.84%, reaching USD 37.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.90 billion
Estimated Year [2026] USD 17.91 billion
Forecast Year [2032] USD 37.05 billion
CAGR (%) 12.84%

A concise orientation to the converging technological, operational, and commercial forces reshaping plant biotechnology equipment procurement and laboratory workflows

The plant biotechnology equipment landscape is undergoing rapid evolution as innovators, service providers, and research institutions seek higher throughput, greater reproducibility, and more integrated workflows. This introduction synthesizes the drivers behind heightened investment and adoption in laboratory and production equipment used for genetic manipulation, sequencing, and phenotyping, while framing the forces reshaping procurement, operations, and collaboration across the sector.

Adoption trends are being driven by the maturing of gene editing techniques, expanded applications of next generation sequencing, and the increasing reliance on automation and single-use technologies to accelerate experimental timelines. At the same time, tighter regulatory scrutiny, supply chain pressures, and the growing emphasis on data outputs and bioinformatics are reshaping how equipment is specified, validated, and serviced. These dynamics are prompting both incumbents and new entrants to re-evaluate product roadmaps, after-sales service models, and partner ecosystems.

For decision-makers, this introduction serves as an orientation to the essential market forces that influence capital planning and operational design. It highlights the confluence of technological maturation, workflow integration, and the commercial impetus to turn laboratory throughput into reliable, reproducible outputs that support downstream breeding, trait development, and biologics discovery. The remainder of this executive summary builds on these themes to explore strategic shifts, trade-policy impacts, segmentation-specific opportunities, regional differences, competitive behaviors, and recommended actions for leaders seeking to translate capability into sustainable advantage.

How modular platforms, recurring consumables, data-driven services, and sustainability priorities are fundamentally reshaping equipment strategies and vendor differentiation

The landscape for plant biotechnology equipment is being transformed by a set of interconnected shifts that extend from the bench to the field and from instrument design to commercial service models. First, modularization and workflow integration are redefining product roadmaps: laboratories increasingly favor platforms that enable rapid handoffs between sample preparation, sequencing or synthesis, and downstream analysis. This emphasis on seamless data and material flow is encouraging vendors to offer bundled solutions, stronger software integration, and pre-validated protocols that reduce time-to-result and ease regulatory validation.

Second, the rise of precision gene editing methods has shifted demand toward instruments and consumables that support fine-grained control and reproducibility. Tools that facilitate CRISPR workflows, from delivery systems to verification by sequencing, are attracting disproportionate attention, prompting suppliers to optimize instrument compatibility with reagents and analytics. Consequently, consumables and service revenue streams are becoming more central to competitive positioning, as recurring purchases of kits, reagents, and software subscriptions provide predictable value beyond initial instrument sales.

Third, digitization and data-centric service offerings are elevating the role of bioinformatics and cloud-enabled visualization in equipment value propositions. Customers expect vendors to support not only raw data generation but also downstream interpretation, which is driving deeper partnerships between instrument manufacturers and analytics providers. Regulatory and quality management considerations are also catalyzing investments in traceability, electronic lab record integration, and validated data pipelines, which in turn influence purchasing criteria and procurement cycles.

Finally, operational resilience and sustainability are emerging cross-cutting themes that inform design and deployment choices. Single-use systems, energy-efficient thermal modules, and supply-chain transparency are increasingly factored into procurement decisions, as institutions weigh total cost of ownership alongside environmental and compliance imperatives. Taken together, these transformative shifts are reshaping the competitive calculus across instrument categories, applications, and end-user segments, and they underscore the need for vendors and buyers to align product innovation with evolving workflow and policy realities.

Assessing how recent US tariff measures reshape sourcing strategies, manufacturing footprints, consumable supply continuity, and procurement risk management across the value chain

The cumulative impact of recent United States tariffs and related trade measures has introduced new variables into procurement planning, supply chain architecture, and pricing strategies for plant biotechnology equipment. At the transactional level, increased import levies on components or finished instruments can erode margins or push list prices higher for end users, creating pressure to re-evaluate sourcing strategies and to explore alternative supply pathways. Procurement teams are consequently reassessing supplier portfolios and specifications to identify components and subsystems that can be sourced domestically or from tariff-favored jurisdictions.

Beyond immediate cost effects, tariffs influence strategic decisions around manufacturing footprint and supplier relationships. Many manufacturers are conducting scenario planning to determine whether localization, nearshoring, or diversification of contract manufacturers will mitigate future trade exposure. These decisions are informed by considerations of production scale, labor skills, intellectual property protection, and regulatory compliance. In some cases, moving assembly or subassembly closer to key markets reduces tariff vulnerability but introduces new complexities in quality control and supplier development timelines.

Tariffs also have downstream consequences for service and consumable supply chains. Recurring revenue streams tied to reagents, cartridges, and single-use disposables may become subject to the same trade frictions, prompting service providers to secure multiple distribution channels and to negotiate longer-term supply contracts to stabilize availability and pricing for customers. For research institutions and companies with global operations, the uncertainty around effective landed costs can delay capital investments and lengthen procurement cycles, particularly for high-value instruments that require extended validation.

Regulatory and policy responses further compound the landscape. Trade actions can trigger reciprocal measures, induce changes in tariff classification, or accelerate bilateral trade negotiations, each of which alters the competitive dynamics for specific technologies. Consequently, commercial teams must integrate trade-policy monitoring into their market surveillance and risk management processes. Additionally, procurement and R&D leaders are increasingly factoring tariff exposure into product design decisions, opting for more modular architectures that allow substitution of affected components without redesigning whole platforms.

In summary, tariffs act as a strategic stress test that exposes reliance on concentrated suppliers and geographically narrow manufacturing footprints. While the immediate effect is often cost pressure, the longer-term responses-reshoring, diversification, contractual hedging, and design modularity-reshape how instruments are produced, sold, and serviced. Stakeholders that proactively incorporate trade-policy risk into sourcing, pricing, and product strategies can reduce disruption, preserve margins, and maintain service continuity for end users.

Segment-driven clarity on instrument subcategories, application demand, technology choices, end-user procurement behavior, and workflow-stage priorities to guide target strategies

A nuanced segmentation lens reveals differentiated opportunities and constraints across instrument types, applications, technologies, end users, and workflow stages. Instruments span bioreactors, DNA sequencers, microarray systems, and PCR systems, with each category exhibiting distinct subcategory dynamics: bioreactors bifurcate into single-use and stainless steel designs that appeal to different scales of production and validation requirements; DNA sequencers split across next generation sequencing platforms and legacy Sanger systems, with NGS driving much of the demand for high-throughput verification; microarray systems are focused on gene expression versus SNP analysis, where each use case informs array density and interpretation needs; and PCR systems are evolving across digital PCR and qPCR modalities, where digital formats are prized for sensitivity and absolute quantification.

Applications provide another axis of differentiation, spanning gene editing, genetic analysis, phenotyping, and tissue culture. Within gene editing, CRISPR dominates adoption curves alongside TALEN and ZFN for certain niche use cases where delivery constraints or intellectual property considerations influence method selection. Genetic analysis skews toward expression analysis and genotyping, each with unique sample throughput and data interpretation demands. Phenotyping workflows increasingly combine image analysis with sensor-based approaches to capture complex trait data, while tissue culture encompasses callus culture and protoplast culture techniques that require specialized incubators and sterile handling solutions.

Technology-driven segmentation further clarifies where investment and innovation are concentrated. CRISPR toolchains leverage plasmid delivery approaches and ribonucleoprotein methods, each with different implications for instrument compatibility and validation. Next generation sequencing has internal technology splits such as platforms aligned with Illumina-style sequencing chemistries and those more closely associated with Ion Torrent-style semiconductor detection, and buyers often weigh read characteristics, run time, and library preparation demands when selecting platforms. PCR technology differentiates along ddPCR and qPCR paths, with the former favored for high-precision quantification and the latter remaining a workhorse for routine assays.

End-user segmentation highlights the diversity of purchasing drivers and support expectations across academic institutions, biotech companies, contract research organizations, and pharmaceutical companies. Academic institutions frequently procure instruments for open-ended research and training and include research centers and universities with differing budget cycles and service needs. Biotech companies encompass agri biotech and pharma biotech players focused on commercialization and scale-up. Contract research organizations span clinical CRO services and broader CRO offerings that prioritize throughput, validated workflows, and vendor interoperability, while pharmaceutical companies cover biologics and small molecule divisions with distinct regulatory and quality management demands.

Finally, workflow-stage segmentation-analysis, sample preparation, and synthesis-sheds light on where value is realized and how vendors can differentiate. Analysis stages increasingly require integrated bioinformatics and data visualization capabilities to turn raw reads or phenotypic images into actionable insights. Sample preparation covers DNA extraction and library preparation, areas where automation and kit standardization substantially reduce variability. Synthesis spans gene synthesis and oligo synthesis, which underpin many downstream workflows and invite strategic partnerships between instrument makers and oligonucleotide suppliers. By mapping technology and product strategies onto these interlocking segmentation tiers, stakeholders can better prioritize product development, channel strategy, and after-sales services to match the nuanced needs of distinct customer cohorts.

Regional procurement rhythms, regulatory expectations, and service network imperatives that shape equipment adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on procurement rhythms, regulatory expectations, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a strong ecosystem of research institutions, biotech startups, and established manufacturers creates a demand profile that favors integrated platforms, robust after-sales service, and local reagent supply chains. This environment also supports rapid early adoption of next generation sequencing and gene editing workflows, while procurement decisions are shaped by institutional grant cycles and private investment patterns.

In Europe, the Middle East & Africa, regulatory harmonization efforts and sustainability commitments are major considerations that inform purchasing criteria, from energy-efficient instrument designs to traceable consumable sourcing. Buyers in these markets often emphasize compliance pathways and documentation that facilitate cross-border research collaborations. Additionally, localized service networks and certified distributors are pivotal for maintaining uptime, particularly for high-throughput sequencing and bioreactor systems used in both academic and industrial settings.

The Asia-Pacific region is marked by rapid capacity expansion, diversified manufacturing bases, and aggressive government support for bioscience capabilities. Demand here spans large-scale agricultural biotech initiatives, contract service expansion, and growing clinical and research sequencing programs. Buyers frequently seek cost-competitive instruments with reliable consumable availability and scalable service agreements. Strategic partnerships with local players and investments in training and support infrastructure are common approaches for vendors seeking durable market presence across this heterogeneous region.

Across all regions, cross-border collaboration, harmonized quality standards, and logistics robustness are recurring themes. Vendors that tailor their go-to-market models to regional procurement rhythms, regulatory idiosyncrasies, and service expectations are better positioned to build long-term customer relationships and to mitigate risks associated with supply interruptions and compliance changes.

Competitive landscape analysis showing how platform incumbents, niche innovators, consumable ecosystems, and service integrators shape long-term advantage

Competitive dynamics in the plant biotechnology equipment space are characterized by a mix of platform incumbents, specialist innovators, and vertically integrated suppliers that blur the lines between instrument vendor and service provider. Established instrument manufacturers compete on platform reliability, throughput, and depth of consumable ecosystems, while niche suppliers focus on performance differentiators such as sensitivity, miniaturization, or automation that address specific workflow bottlenecks. This competitive tension drives continuous incremental innovation as vendors refine optics, fluidics, thermal control, and software to gain adoption in targeted applications.

Concurrently, reagent and consumable suppliers wield outsized influence on customer lock-in and recurring revenue streams. The commercial logic of pairing instruments with proprietary reagents or cartridges supports predictable service income and cements long-term customer relationships. As a result, strategic alliances between platform manufacturers and consumable specialists are common, and some players elect to vertically integrate to capture more of the downstream revenue pool. Services companies and contract research organizations also act as critical intermediaries, offering high-throughput access to technologies for customers that prefer project-based engagement over capital investment.

Market entrants tend to pursue one of two playbooks: differentiation through a narrow technical advance that addresses a specific pain point, or broad platform development that emphasizes compatibility and enterprise integration. The former enables faster market entry and targeted adoption, while the latter demands larger investments in regulatory validation and support infrastructure but offers higher lifetime customer value. Across these approaches, key success factors include robust validation data, clear total cost of ownership narratives, accessible training and support, and transparent compatibility with established workflows and data systems.

Overall, companies that balance innovation with service excellence, that cultivate strong channel partnerships, and that build ecosystems around consumables and analytics are best poised to capture sustainable advantage. Competitive advantage increasingly depends not only on instrument performance but also on the ability to deliver validated, end-to-end workflows that reduce time-to-insight for researchers and developers.

Practical strategic moves for manufacturers and service providers to build resilience, deepen customer value, and seize product and service differentiation opportunities

Industry leaders should take decisive, proactive steps to convert disruptive trends into strategic advantage through targeted investments in manufacturing flexibility, product architecture, and customer engagement. First, accelerate modular product design so that affected subassemblies can be substituted without full platform redesign; this reduces exposure to tariff-driven supply shocks and shortens qualification timelines for localized production. By designing for modularity, firms can also offer scalable configurations that serve both discovery labs and commercial-scale operations, broadening addressable use cases.

Second, fortify consumable and reagent availability through diversified sourcing and strategic inventory agreements that prioritize continuity for high-value customers. Establishing multiple certified suppliers for critical components and negotiating tiered supply contracts with lead-time protections will help stabilize service levels and preserve customer trust. In parallel, invest in service infrastructure and training to ensure rapid field support, which is increasingly a differentiator in procurement decisions.

Third, expand software and analytics offerings to shift value capture beyond hardware. Integrated bioinformatics, validated data pipelines, and subscription-based visualization platforms improve user outcomes and increase customer stickiness. These digital offerings should be developed with regulatory traceability and auditability in mind to meet end-user compliance needs. Strategic partnerships or acquisitions of analytics specialists can accelerate capability build-out when organic development would be slower.

Fourth, adopt a regionally nuanced go-to-market posture that reflects the specific procurement patterns, regulatory requirements, and support expectations of each territory. Local partnerships, certification programs, and tailored financing solutions can lower adoption friction and foster deeper customer relationships. Lastly, incorporate trade-policy scenario planning into product and sourcing strategies. Establish cross-functional teams that continuously monitor tariff movements, negotiate flexible contracts, and model alternative manufacturing footprints to maintain resilience under varying policy regimes.

By implementing these actions, industry leaders can secure more predictable revenue streams, reduce operational vulnerability, and enhance their ability to meet the differentiated needs of research institutions, biotech innovators, CROs, and pharmaceutical developers.

A mixed-methods research approach combining primary stakeholder interviews, technical product reviews, and policy scanning to produce validated, actionable insights

This research synthesis is built from a triangulated methodology combining primary qualitative interviews, secondary literature synthesis, and targeted product and policy scans. Primary inputs include structured interviews with laboratory directors, procurement specialists, instrument engineers, and commercial leaders across academic, industrial, and service-provider segments. These discussions focused on procurement drivers, validation workflows, supply-chain sensitivities, and the role of data analytics in instrument adoption.

Secondary research comprised a review of technical whitepapers, regulatory guidance documents, patent filings, and industry briefings to contextualize trends in technology maturation and standardization. Industry product specifications and publicly available validation studies were analyzed to compare performance characteristics across instrument classes and to identify recurring pain points in sample preparation, throughput, and data handling. Policy and trade analyses were incorporated to assess how recent tariff measures and import controls influence sourcing decisions and manufacturing footprints.

Analytical approaches included cross-segmentation mapping to align instrument attributes with application needs and end-user procurement behavior, as well as scenario modeling to evaluate the operational impact of supply interruptions and policy shifts. Data validation steps involved corroborating primary interview themes with documentary evidence and seeking multiple independent confirmations for claims related to technology adoption and procurement timelines. Confidentiality safeguards were maintained to protect proprietary information shared by participants, and synthesized findings were normalized to avoid overreliance on single-source perspectives.

This mixed-method methodology yields a balanced view that integrates real-world operational insights with technical performance assessments and policy-awareness, providing decision-makers with actionable context rather than speculative forecasts.

Summative implications showing why workflow integration, supply resiliency, and data-centric services determine competitive success across the industry

In conclusion, the plant biotechnology equipment landscape is in the midst of a strategic inflection driven by technological maturation, evolving procurement expectations, and geopolitical trade considerations. Instrument innovation is converging with software-driven analytics and consumable-centric business models, shifting the competitive focus from point instruments to validated, end-to-end workflows that deliver reproducible outputs. This evolution favors vendors who can pair technical performance with robust service networks, validated protocols, and supply-chain resilience.

Trade-policy developments introduce a new imperative for manufacturers and buyers to design flexibility into sourcing and product architecture. While tariffs and related measures create short-term cost and timeline pressures, the longer-term response-diversified manufacturing, modular design, and tighter supplier partnerships-will determine which organizations can sustain performance and customer trust. Regional market dynamics further shape strategies, as diverse regulatory expectations and procurement behaviors require tailored go-to-market models.

Ultimately, stakeholders that align R&D investments, commercial models, and operational practices around workflow integration, data integrity, and resiliency will capture disproportionate value. The recommendations and insights presented here are intended to help executives prioritize actions that reduce risk, accelerate adoption, and strengthen their competitive position in an increasingly complex and opportunity-rich sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plant Biotechnology Equipment Market, by Instrument Type

  • 8.1. Bioreactors
    • 8.1.1. Single Use
    • 8.1.2. Stainless Steel
  • 8.2. DNA Sequencers
    • 8.2.1. Next Generation Sequencing
    • 8.2.2. Sanger Sequencing
  • 8.3. Microarray Systems
    • 8.3.1. Gene Expression
    • 8.3.2. SNP Analysis
  • 8.4. PCR Systems

9. Plant Biotechnology Equipment Market, by Technology

  • 9.1. CRISPR Tools
    • 9.1.1. Plasmid Delivery
    • 9.1.2. Ribonucleoprotein
  • 9.2. Next Generation Sequencing
  • 9.3. PCR Technology

10. Plant Biotechnology Equipment Market, by Workflow Stage

  • 10.1. Analysis
    • 10.1.1. Bioinformatics
    • 10.1.2. Data Visualization
  • 10.2. Sample Preparation
    • 10.2.1. DNA Extraction
    • 10.2.2. Library Preparation
  • 10.3. Synthesis
    • 10.3.1. Gene Synthesis
    • 10.3.2. Oligo Synthesis

11. Plant Biotechnology Equipment Market, by Application

  • 11.1. Gene Editing
  • 11.2. Genetic Analysis
    • 11.2.1. Expression Analysis
    • 11.2.2. Genotyping
  • 11.3. Phenotyping
    • 11.3.1. Image Analysis
    • 11.3.2. Sensor Based
  • 11.4. Tissue Culture
    • 11.4.1. Callus Culture
    • 11.4.2. Protoplast Culture

12. Plant Biotechnology Equipment Market, by End User

  • 12.1. Academic Institutions
    • 12.1.1. Research Centers
    • 12.1.2. Universities
  • 12.2. Biotech Companies
    • 12.2.1. Agri Biotech
    • 12.2.2. Pharma Biotech
  • 12.3. Contract Research Organizations
  • 12.4. Pharma Companies

13. Plant Biotechnology Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Plant Biotechnology Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Plant Biotechnology Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Plant Biotechnology Equipment Market

17. China Plant Biotechnology Equipment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Danaher Corporation
  • 18.8. LabRepCo
  • 18.9. LemnaTec GmbH
  • 18.10. LGC Limited
  • 18.11. Merck KGaA
  • 18.12. Microsil India Pvt. Ltd.
  • 18.13. Narang Scientific Works Pvt. Ltd.
  • 18.14. Neu-tec Group Inc.
  • 18.15. PerkinElmer, Inc.
  • 18.16. Sartorius AG
  • 18.17. Shimadzu Corporation
  • 18.18. Tecan Group Ltd.
  • 18.19. Thermo Fisher Scientific Inc.
  • 18.20. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SNP ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PLASMID DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RIBONUCLEOPROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DATA VISUALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY OLIGO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY EXPRESSION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY IMAGE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SENSOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CALLUS CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PROTOPLAST CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY AGRI BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICROARRAY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY CRISPR TOOLS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GENETIC ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY PHENOTYPING, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY TISSUE CULTURE, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOTECH COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY INSTRUMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY BIOREACTORS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY DNA SEQUENCERS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN PLANT BIOTECHNOLOGY EQUIPMENT MARKET SIZE, BY MICR